Skip to main content
. 2010 May-Jun;2(3):233–255. doi: 10.4161/mabs.2.3.11782

Figure 2.

Figure 2

Strategy and timing for assessment of immunotoxicity with immunomodulatory mAbs. A range of immunological tests can be applied at different stages of the product development program of a mAb. *May be required depending on the MoA of the mAb and/or to investigate the mechanism of any immune function defects observed in non-clinical or clinical studies.